Clearline Capital LP increased its holdings in Novanta Inc. (NASDAQ:NOVT – Free Report) by 37.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 322,369 shares of the technology company’s stock after acquiring an additional 87,997 shares during the period. Novanta comprises approximately 1.9% of Clearline Capital LP’s portfolio, making the stock its 10th biggest holding. Clearline Capital LP owned about 0.90% of Novanta worth $38,359,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Assetmark Inc. lifted its holdings in Novanta by 22.4% during the fourth quarter. Assetmark Inc. now owns 541 shares of the technology company’s stock worth $64,000 after acquiring an additional 99 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Novanta by 120.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 427 shares of the technology company’s stock worth $51,000 after acquiring an additional 233 shares during the period. Van ECK Associates Corp lifted its holdings in Novanta by 17.2% during the third quarter. Van ECK Associates Corp now owns 1,627 shares of the technology company’s stock worth $163,000 after acquiring an additional 239 shares during the period. Amundi lifted its holdings in Novanta by 1.4% during the third quarter. Amundi now owns 18,287 shares of the technology company’s stock worth $1,908,000 after acquiring an additional 245 shares during the period. Finally, Nicolet Advisory Services LLC lifted its holdings in Novanta by 7.1% during the third quarter. Nicolet Advisory Services LLC now owns 4,046 shares of the technology company’s stock worth $409,000 after acquiring an additional 269 shares during the period. 98.35% of the stock is owned by hedge funds and other institutional investors.
Novanta Price Performance
Novanta stock opened at $151.43 on Thursday. Novanta Inc. has a 52 week low of $98.27 and a 52 week high of $171.85. The business has a 50-day simple moving average of $145.35 and a 200 day simple moving average of $133.73. The company has a quick ratio of 2.69, a current ratio of 3.56 and a debt-to-equity ratio of 0.15. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of 109.73 and a beta of 1.68.
Insider Activity
In other news, CEO Matthijs Glastra sold 7,500 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $150.43, for a total transaction of $1,128,225.00. Following the completion of the sale, the chief executive officer directly owned 42,761 shares in the company, valued at approximately $6,432,537.23. This represents a 14.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.20% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on NOVT shares. Wall Street Zen downgraded Novanta from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Novanta in a research note on Friday, April 17th. Finally, Robert W. Baird set a $180.00 price objective on Novanta in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $180.00.
Check Out Our Latest Research Report on Novanta
Novanta Company Profile
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
Featured Stories
- Five stocks we like better than Novanta
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT – Free Report).
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
